Clinical efficacy of Xuebijing injection for the treatment of sepsis: A retrospective cohort study.
10.1016/j.joim.2024.08.006
- Author:
Zhao-Tang GONG
1
;
Hong-Xin YANG
2
;
Ben-Ben ZHU
3
;
Huan-Huan LIU
4
;
Guleng SIRI
5
,
6
Author Information
1. Department of Pharmacy, Inner Mongolia Autonomous Region People's Hospital, Hohhot 010017, Inner Mongolia Autonomous Region, China; Department of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, Inner Mongolia Autonomous Region, China.
2. Department of Pharmacy, Inner Mongolia Autonomous Region People's Hospital, Hohhot 010017, Inner Mongolia Autonomous Region, China.
3. Department of Pharmacy, Peking University Cancer Hospital (Inner Mongolia Campus)/Affiliated Cancer Hospital of Inner Mongolia Medical University, Hohhot 010020, Inner Mongolia Autonomous Region, China.
4. Department of Pharmacy, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100010, China.
5. Department of Pharmacy, Inner Mongolia Autonomous Region People's Hospital, Hohhot 010017, Inner Mongolia Autonomous Region, China; Inner Mongolia Academy of Medical Sciences, Hohhot 010017, Inner Mongolia Autonomous Region, China. Electronic address: srgl985@
6. com.
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords:
Inflammatory factors;
Mortality;
Sepsis;
Septic shock;
Xuebijing injection
- MeSH:
Humans;
Drugs, Chinese Herbal/administration & dosage*;
Sepsis/mortality*;
Retrospective Studies;
Male;
Female;
Middle Aged;
Aged;
Treatment Outcome;
Anti-Bacterial Agents/administration & dosage*;
C-Reactive Protein/analysis*;
Carbapenems/therapeutic use*;
Length of Stay;
Injections;
Adult;
Drug Therapy, Combination;
Procalcitonin/blood*
- From:
Journal of Integrative Medicine
2024;22(6):645-651
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:The objective of this study was to investigate the clinical efficacy and safety of treating sepsis patients with Xuebijing injection (XBJI).
METHODS:We conducted a retrospective analysis of 418 patients who experienced severe infections and were treated with XBJI from June 2018 to June 2021. Propensity score matching was used to match the patient cases. The study population included 209 pairs of cases (418 individuals), and the analysis included data from before and after a 14-day course of treatment with carbapenem alone, or carbapenem with XBJI.
RESULTS:There were no significant differences in the 14-day mortality or length of hospital stay (P > 0.05) between the two groups. The combined treatment group had more patients with C-reactive protein that returned to normal levels (compared to baseline) than the non-combined treatment group (14.4% vs 8.1%; odds ratio [OR]: 0.528; 95% confidence interval [CI]: 0.282-0.991; P = 0.026). Similarly, the combined treatment group had higher procalcitonin attainment rate (55.0% vs 39.7%; OR: 0.513; 95% CI: 0.346-0.759; P = 0.001) than the non-combined treatment group. Further, more patients in the combined treatment group achieved normal creatinine levels than in the non-combined treatment group (64.1% vs 54.1%; OR: 0.659; 95% CI: 0.445-0.975; P = 0.037).
CONCLUSION:The combination of XBJI with carbapenem did not reduce the 14-day mortality rate of patients with severe infection, but it was able to reduce the level of inflammatory factors in patients with sepsis, and had a protective effect on liver and kidney function. Please cite this article as: Gong ZT, Yang HX, Zhu BB, Liu HH, Siri GL. Clinical efficacy of Xuebijing injection for the treatment of sepsis: A retrospective cohort study. J Integr Med. 2024; 22(6): 645-651.
